Inspiring publication of our partner University of Michigan

Inspiring publication of our partner University of Michigan about improving outcomes in patients with type 2 diabetes

The PRIME-CKD consortium is proud to share with you a new publication by our partner Michigan University.

This study looks into the relationship between the sodium-glucose co-transporter 2 (SGLT2) inhibitor canagliflozin and urinary epidermal growth factor (uEGF) and if changes in uEGF improve outcomes in patients with type 2 diabetes (T2D). They showed that increased uEGF is associated with reduced risk of kidney disease progression in T2D. Also, canagliflozin increased urine- and kidney tissue expression of EGF which was associated with a tubular repair pathway. The published data support a role for EGF in the kidney-protective effect of SGLT2 inhibitors, and they suggest that EGF may be used as a pharmacodynamic marker of response to SGLT2 inhibition.

You can find more information about this excellent article here.